Aprea Therapeutics reports FY2025 net loss of $12.6M; APR-1051 shows two partial responses

Aprea Therapeutics, Inc.

Cash and equivalents $14.6M at Dec 31, 2025; plus Jan 2026 private placement of $5.6M funds operations into Q1 2027.
Net loss $12.6M ($1.93/share) for FY2025 vs $13.0M ($2.35/share) in FY2024; R&D spend down to $7.0M from $9.4M.
APR-1051 (WEE1 inhibitor) yields two unconfirmed partial responses in PPP2R1A-mutated endometrial cancer; dose escalation ongoing at 220 mg.
ATRN-119 (ATR inhibitor) RP2D set at 1,100 mg; monotherapy enrollment paused, exploring combination studies.
Appointed Eugene Kennedy, MD, as Chief Medical Advisor in February 2026 to support next phase of development.

item 2.02 item 8.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Aprea Therapeutics, Inc. reported financial results for the fourth quarter and full year ended December 31, 2025.

Period: the fourth quarter and full year ended December 31, 2025
Result: reported results

Exact text from the filing

On March 16, 2026, Aprea Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the three and twelve months ended December 31, 2025

View on SEC.gov

20 earnings releases filed in the last 30 days. Browse all earnings releases →

Aprea Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-26-028046

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.